The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|October 26, 2015
Dow Pharma Launches Polymer for Coating Barrier Membranes
Author(s)Pharmaceutical Technology Editors
Dow introduces solvent-free productivity technology for coating barrier membranes.
Advertisement
Dow Pharma and Food Solutions has introduced ETHOCEL HP, an ethylcellulose polymer for multi-particulate and taste masking applications. The technology, which was designed specifically for rotor coater systems, can be used to dry coat barrier membranes in shorter coating times, at higher efficiencies and without the need for solvents, the company reports. The product was introduced to the North American market at the 2015 annual meeting of the American Association of Pharmaceutical Scientists in Orlando, FL.
Trials conducted by Dow demonstrated that ETHOCEL HP offers a step improvement in barrier membrane coating efficiency, with 98-99% greater coating efficiency when compared to solvent or aqueous ethylcellulose systems. Improved coating efficiency could provide pharmaceutical companies with opportunities for raw material cost savings and an easier clean-up step, Dow reports.
ETHOCEL HP will be available for sampling in 2016.
Dow also announced the commercial availability of AFFINISOL HPMC HME, a cellulosic polymer for drug solubilization.
Source:
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Advertisement
Advertisement